Skip to main content

and
  1. No Access

    Article

    Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

    This phase 1 study (Clinicaltrials.gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib...

    S K Kumar, I Flinn, S J Noga, P Hari, R Rifkin, N Callander, M Bhandari in Leukemia (2010)